Back to top

Array BioPharma (ARRY) Looks Good: Stock Adds 5.2% in Session

Read MoreHide Full Article

Array BioPharma Inc. (ARRY - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 26.9% in the past one-month time frame.

The company has seen no estimate revisions over the past few weeks and the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Array BioPharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.  

A better-ranked stock in the Medical - Biomedical and Genetics industry is Genomic Health, Inc. (GHDX - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ARRY going up? Or down? Predict to see what others think: Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Genomic Health, Inc. (GHDX) - free report >>

Array BioPharma Inc. (ARRY) - free report >>

More from Zacks Tale of the Tape

You May Like